DEA’s Resistance To Cannabis Rescheduling Ignites Policy Clash
A recent article in The Wall Street Journal has shed light on escalating tensions between the White House and the Drug Enforcement Administration (DEA) over proposals to reclassify marijuana. The pushback from some DEA officials stems from doubts about cannabis’s medicinal benefits and its potential for addiction.
Clash With Health Department Findings
This resistance is notably in conflict with the Department of Health and Human Services (HHS) findings from January, which acknowledged cannabis as having an accepted medical use in treatment in the United States. The HHS documents also suggested that cannabis has a lower abuse potential than substances in Schedules I and II, a stance that contrasts with the DEA’s apprehensions.
DEA’s Concerns And Independent Review
The DEA has voiced concerns over the THC potency in cannabis, sparking debate …